Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Aug 21;14(12):2083–2103. doi: 10.1080/15548627.2018.1503146

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 Informa UK Limited, trading as Taylor & Francis Group

PMC Copyright notice

Figure 6. — Sorafenib treatment alleviates murine liver fibrosis by inducing HSC ferroptosis. Fifty mice were randomly divided into 5 groups of 10 animals each with comparable mean body weight. Mice of 5 groups were treated with Sham, BDL+ VA-Lip-Control-siRNA, BDL+ VA-Lip-Control-siRNA+ sorafenib, BDL+ VA- Lip-ELAVL1-siRNA, or BDL+ VA-Lip-ELAVL1-siRNA+ sorafenib. (a and b) The pathological changes of the livers were observed by macroscopic examination. Scale bars: 1 cm. Representative photographs were shown. Thin sections (4 μm) were stained with H&E, Sirius Red, and Masson for histopathological study. The liver fibrosis stage was assessed by Ishak scale. Liver hydroxyproline level was determined using the Hydroxyproline Assay Kit (n = 6 in every group, *, p < 0.05, **, p < 0.01). (c) Immunohistochemical staining of ACTA2 and COL1A1 was determined. Scale bars: 50 μm. Representative photographs were shown (n = 6 in every group, *, p < 0.05, **, p < 0.01, ***, p < 0.001).